High-quality business currently experiencing weak market structure. Monitor for trend reversal. Valuations remain demanding and supported by current metrics.
SENTINEL REVIEW
Ambuja Cements Limited (AMBUJACEM)•Updated yesterday
🚨 Structural Deterioration Signature: In FY2026, Ambuja Cements Limited is experiencing severe earnings quality strain, marked by a 9.3% YoY deterioration in reported net profit to ₹5,637 Cr, compounded by a 10.1% YoY revenue contraction. Profitability is being hollowed out by margin compression: EBIT margins fell to 5.6% from 15.7% YoY, signaling significant internal efficiency stress. This operating deterioration is reflected in elevated capex and working capital pressures: elevated capex of 57.6% of revenue and receivable days rising to 20.2, contributing to a 5.0% drop in operating cash flow to ₹5,361 Cr. Against this liquidity strain, total debt expanded 96.8% to ₹52.8 Cr, pushing interest coverage down to 1.86x and entering Flagium's heightened surveillance range.
- ✓Risk score improved (QoQ change: -5 pts)
- ✓Profitability margins pressure eased (Margin Compression resolved)
- ✗Growth expectations are demanding
- ✗Market structure is declining (Stage 4)
- ✗Institutional flow regime is Strong Distribution (-2.12σ)
- ✗Share price is down -6.1% this quarter (from ₹374 on 30 Sept to ₹351.2)
- 🟢No severe forensic red flags active for AMBUJACEM
- 🟢Margin Compression resolved in latest filing; verify sustainability in next filing
- 🟢Maintain routine quarterly surveillance; no governance escalation required
- 3.3 ptsEarnings Quality
- 2.6 ptsGrowth Sustainability
- 1.1 ptsBalance Sheet Stress
Divergence Radar
Structural Matrix
Risk vs Price TimelineVisualizing the historical relationship between the structural risk score and stock price movement over time.
| Duration | Perf. | Sector Avg | Divergence |
|---|---|---|---|
| 1 Week | -2.42% | -1.46% | -0.96% |
| 1 Month | -6.18% | -6.69% | +0.51% |
| 6 Months | -20.54% | +6.82% | -27.37% |
| 1 Year | -36.4% | +8.93% | -45.32% |
| 2 Year | -38.09% | +47.64% | -85.74% |
| 3 Year | -15.27% | +125.5% | -140.76% |
Business Analysis Methodology
Business analysis focuses on structural risk inside the company. Flagium monitors earnings quality, balance sheet strength, liquidity, governance, competitive position, and growth sustainability to identify areas where risk may be increasing or decreasing before it becomes obvious in reported results.
Financial profile is stable with manageable leverage. Pressure is receding in project execution and margins. This indicates that forensic pressure is currently receding. Risk levels are improving.
Risk Score Composition
Investment Risk Thesis
Current risk score has risen from 0 → 7 over 13 quarters.
- Sustainability of earnings recovery
- Operating cash flow sustainability
- Working capital discipline
Risk Drivers (Active Warnings)
No active warnings detected.
Primary Driver & Insights
Forensic risk profile is stable. No severe operating or financial anomalies are currently pressure-testing business resilience.
Active Risk Objects (6)Free Preview (2 of 6)
Operating margin declined by 10.1 bps YoY for two consecutive quarters.
Operating efficiency is stabilizing. The rate of margin deterioration has slowed.
AMBUJACEM: Net Profit collapsed by 86.0% from FY2025 Q3 to FY2026 Q3.
Earnings quality is stabilizing. The reliance on non-operational items is receding.
Unlock All 6 Forensic Signals (4 Additional Warnings Gated)
Free accounts preview the top 2 highest-impact warning signals. Upgrade to Flagium Pro to inspect all 6 active forensic detectors, multi-quarter duration streaks, and financial stress metrics for Ambuja Cements Limited.
Statutory Note: Forensic signals are algorithmic quantitative observations derived from publicly filed XBRL disclosures and do not constitute allegations of legal misconduct or investment recommendations.
Unlock Interactive Signal Evidence Dossier
Access complete multi-quarter financial evidence, 5-KPI snapshot strips, diagnostic hypotheses, and 1-page forensic PDF dossiers for Ambuja Cements Limited.
Structural Risk Attribution
Deterministic quarter-on-quarter causal decomposition grounded in statutory exchange filings.
Structural History · Last 12 QuartersHistorical Trajectory (12Q)
Risk improved moderately (-5.0 pts), driven by Margin Compression (-16.2 pts).
12-Quarter Structural Regimes & Landmark Inflections12Q Structural Regimes & Inflections
Risk deteriorated materially (+34.0 pts), driven by new Inventory Stress (+14.4 pts) and new Capex Efficiency Stress (+10.8 pts).
Business Resilience & Benchmark Context
Overall: STRONGPEER COMPARISON MATRIX
Ranked surveillance & credit risk comparison against sector peers
Stable
Stable
Watch
Watch
Watch
Watch
* Peer comparison is based on risk signals, not valuation or returns.
Unlock 5-Year Forensic Divergence Cockpit
Access multi-year visual divergence charts (EBITDA vs CFO Cash Gap, Receivables Decoupling Spread, and Debt vs FCF Burn) for Ambuja Cements Limited.
FINANCIAL STATEMENTS
Working Capital & Forensic Monitor
Operating Cycle Disclosures·10 Fiscal Years
Working Capital Schedule (INR Cr)
| Metric / Ratio | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Trade Receivables(₹ Cr) | 1,868 | 1,590 | 1,213 | 1,154 | — | — | — | — | — | — |
Inventories(₹ Cr) | 4,552 | 4,248 | 3,609 | 3,273 | — | — | — | — | — | — |
Trade Payables(₹ Cr) | 4,185 | 2,759 | 3,109 | 2,774 | — | — | — | — | — | — |
Net Working Capital(₹ Cr) | 2,236 | 3,079 | 1,713 | 1,653 | — | — | — | — | — | — |
Working Capital / Sales(%) | 5.4% | 8.2% | 5.0% | 4.2% | — | — | — | — | — | — |
Cash Conversion & Operating Cycle (Days)
| Metric / Ratio | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Cash Conversion Cycle (CCC)(days) | 19d | 29d | 18d | 15d | — | — | — | — | — | — |
Debtor Days (DSO)(days) | 16d | 15d | 13d | 11d | — | — | — | — | — | — |
Inventory Days (DIO)(days) | 40d | 41d | 38d | 30d | — | — | — | — | — | — |
Creditor Days (DPO)(days) | 37d | 27d | 33d | 26d | — | — | — | — | — | — |
Forensic Accounting Monitor & Divergences
| Metric / Ratio | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Receivable Growth vs Sales (Δ)(%) | +7.4% | +21.3% | +18.6% | — | — | — | — | — | — | — |
Inventory Growth vs Sales (Δ)(%) | -2.9% | +7.9% | +23.7% | — | — | — | — | — | — | — |
Asset Growth vs Sales (Δ)(%) | +0.6% | +14.1% | +39.7% | — | — | — | — | — | -5.0% | — |
Earnings-to-Cash Divergence (PAT - CFO)(₹ Cr) | 276 | 1,863 | -908 | 2,289 | — | -1,598 | — | — | 1,270 | -1,471 |
Accrual Ratio (Accruals / Avg Assets)(%) | 0.3% | 2.5% | -1.6% | 4.4% | — | — | — | — | 3.5% | -4.1% |
Operating Cash Realisation (CFO / EBITDA)(%) | 149.8% | 55.6% | 99.6% | 18.3% | — | 100.8% | — | — | 42.5% | 88.5% |
Capitalisation Intensity (CWIP / Assets)(%) | — | — | — | — | — | — | — | — | — | — |
Concall & Management Takeaways
No investor earnings call transcripts transcribed for this scrip.
Earnings call intelligence is automatically populated when companies conduct quarterly earnings calls with institutional investors and publish transcripts.
Business quality remains strong.
Current forensic pressure is elevated and improving.
Key risks remain concentrated in growth sustainability and operating leverage.
The structural architecture is currently robust. Capital resilience buffers in earnings quality remain well-maintained against forensic benchmarks. Systematic scans of operational margins and profitability metrics confirm the absence of material structural stress. Initial structural recovery is visible; monitor for a sustained return to resilience.
Market Expectation Engine
Investor Translation • What the market price is expecting
Expectation EngineAt the current price of ₹351, the market expects this company to grow its revenue by 25.2% every year for the next 5 years. If you think the company will grow faster than 25.2%, current market prices reflect a discount relative to that growth assumption.
Sentinel Takeaway:The market expects future growth significantly above the company's historical delivery. Current market expectations appear demanding relative to the business's track record, resulting in higher expectation risk.
Using the Implied Revenue Model, the market is pricing AMBUJACEM for 25.2% implied revenue growth versus 1.5% observed 3Y revenue CAGR. Current expectations appear demanding, and trailing fundamentals provide moderate support.
Business Delivery Capacity
Performance quality vs historical benchmarksHistorical business performance currently provides moderate support for the market's implied growth assumptions. Improvement in revenue growth and operating efficiency would strengthen expectation support.
WHY IS EXPECTATION RISK ELEVATED?
Valuation Context
WHAT MUST HAPPEN FOR CURRENT PRICE TO BE CORRECT?
| Assumption Metric | Required (To justify current price) | Historical Delivery (Average) | Fulfillment Assessment |
|---|---|---|---|
| Revenue Growth (CAGR) | 25.2% | 1.5% | Aggressive |
| Operating Margin (EBIT) | 7.3% | 13.6% | Achievable |
| Free Cash Flow Conversion | -33.1% | -32.6% | Achievable |
*Required metrics indicate the operating efficiency and revenue expansion parameters that must be sustained long-term to justify the current stock price.
The current valuation assumes business performance well above the company's historical record. Historical operating performance currently provides limited evidence that these expectations are sustainable. Continued stronger profitability and stronger cash generation would be required to justify current pricing.
Market Structure Methodology
Flagium separates Business Risk from Market Structure. Business analysis explains what is happening inside the company. Market Structure measures how investors are behaving through price trends, momentum, participation, and institutional activity. Divergences between the two often reveal important transitions before they become obvious.
The stock remains in a confirmed Stage 4 declining phase. Institutional participation has also deteriorated, compounding the weak trend as momentum continues to deteriorate. Current price action does not yet confirm a structural recovery.
What Is Driving Market Structure?
Price structure remains weak despite stable underlying financial risk.
Market Cycle Stage Analysis
Stan Weinstein 4-Stage CycleMomentum & Institutional Flow
Methodology & Regulatory Disclaimer
Flagium AI is an automated financial data analytics and research platform providing quantitative risk, forensic, and valuation analytics for informational and educational purposes only. Flagium AI is not registered with SEBI as a Research Analyst or Investment Adviser under SEBI regulations. These analytics do not constitute financial planning, investment advice, or recommendations to buy, sell, or hold any security.
Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered Investment Adviser before acting on any data presented.
📬 Flagium Risk Brief — Track forensic risks on AMBUJACEM & 3 market anomalies weekly
See a sample issue →